174 related articles for article (PubMed ID: 32060643)
1. A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level.
Liu Q; Wang K; Huang R; Tong X; Jiang T; Wang J; Yang P
J Cancer Res Clin Oncol; 2020 Mar; 146(3):579-591. PubMed ID: 32060643
[TBL] [Abstract][Full Text] [Related]
2. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
3. Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma.
Chen Y; Guo Y; Chen H; Ma F
Front Neurol; 2020; 11():573264. PubMed ID: 33329315
[No Abstract] [Full Text] [Related]
4. Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
Liu YQ; Wu F; Li JJ; Li YF; Liu X; Wang Z; Chai RC
Front Oncol; 2019; 9():1433. PubMed ID: 31921684
[No Abstract] [Full Text] [Related]
5. Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling.
Wang Q; Wang Z; Li G; Zhang C; Bao Z; Wang Z; You G; Jiang T
Aging (Albany NY); 2018 Aug; 10(8):1977-1988. PubMed ID: 30115812
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
7. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
Reuss DE; Mamatjan Y; Schrimpf D; Capper D; Hovestadt V; Kratz A; Sahm F; Koelsche C; Korshunov A; Olar A; Hartmann C; Reijneveld JC; Wesseling P; Unterberg A; Platten M; Wick W; Herold-Mende C; Aldape K; von Deimling A
Acta Neuropathol; 2015 Jun; 129(6):867-73. PubMed ID: 25962792
[TBL] [Abstract][Full Text] [Related]
8. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
Wu F; Chai RC; Wang Z; Liu YQ; Zhao Z; Li GZ; Jiang HY
Carcinogenesis; 2019 Jul; 40(7):853-860. PubMed ID: 30877769
[TBL] [Abstract][Full Text] [Related]
9. Integrative Analysis of DNA Methylation and Gene Expression Identify a Three-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas.
Zeng WJ; Yang YL; Liu ZZ; Wen ZP; Chen YH; Hu XL; Cheng Q; Xiao J; Zhao J; Chen XP
Cell Physiol Biochem; 2018; 47(1):428-439. PubMed ID: 29794476
[TBL] [Abstract][Full Text] [Related]
10. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of an Immune-Related Gene Pairs Signature in Grade II/III Glioma.
Zhang X; Ping S; Wang A; Li C; Zhang R; Song Z; Gao C; Wang F
Int J Gen Med; 2021; 14():8611-8620. PubMed ID: 34849006
[TBL] [Abstract][Full Text] [Related]
14. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of genes based on chr1p/19q co-deletion reveals a robust 4-gene prognostic signature for lower grade glioma.
Zhang C; Yu R; Li Z; Song H; Zang D; Deng M; Fan Y; Liu Y; Zhang Y; Qu X
Cancer Manag Res; 2019; 11():4971-4984. PubMed ID: 31213913
[No Abstract] [Full Text] [Related]
16. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.
Wijnenga MMJ; French PJ; Dubbink HJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Fleischeuer R; Dirven CMF; Vincent AJPE; van den Bent MJ
J Neurooncol; 2018 Sep; 139(2):349-357. PubMed ID: 29663171
[TBL] [Abstract][Full Text] [Related]
18. Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients.
Ye N; Jiang N; Feng C; Wang F; Zhang H; Bai HX; Yang L; Su Y; Huang C; Wanggou S; Li X
J Cancer; 2019; 10(22):5536-5548. PubMed ID: 31632497
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic Profiling Identifies a DNA Repair-Related Signature as a Novel Prognostic Marker in Lower Grade Gliomas.
Zeng F; Liu X; Wang K; Zhao Z; Li G
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2079-2086. PubMed ID: 31533943
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
